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Abstract
Background: To describe the 6-year safety and efficacy of etanercept (ETN) in children with extended oligoarticular
juvenile idiopathic arthritis (eoJIA), enthesitis-related arthritis (ERA), and psoriatic arthritis (PsA)
Methods: Patients who completed the 2-year, open-label, phase III CLinical Study In Pediatric Patients of Etanercept
for Treatment of ERA, PsA, and Extended Oligoarthritis (CLIPPER) were allowed to enroll in its 8-year long-term
extension (CLIPPER2). Children received ETN at a once-weekly dose of 0.8 mg/kg, up to a maximum dose of 50 mg/
week. Efficacy assessments included the JIA core set of outcomes, the JIA American College of Rheumatology
response criteria (JIA-ACR), and the Juvenile Arthritis Disease Activity Score (JADAS). Efficacy data are reported as
responder analyses using a hybrid method for missing data imputation and as observed cases. Safety assessments
included treatment-emergent adverse events (TEAEs).
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Results: Out of 127 patients originally enrolled in CLIPPER, 109 (86%) entered CLIPPER2. After 6 years
of trial participation (2 years in CLIPPER and 4 years in CLIPPER2), 41 (32%) patients were still taking ETN,
13 (11%) entered the treatment withdrawal phase after achieving low/inactive disease (of whom 7 had
to restart ETN), 36 (28%) discontinued treatment for other reasons but are still being observed, and 37 (29%)
discontinued treatment permanently. According to the hybrid imputation analysis, proportions of patients achieving
JIA ACR90, JIA ACR100, and JADAS inactive disease after the initial 2 years of treatment were 58%, 48%, and 32%,
respectively. After the additional 4 years, those proportions in patients who remained in the trial were 46%, 35%, and 24%.
Most frequently reported TEAEs [n (%), events per 100 patient-years] were headache [28 (22%), 5.3], arthralgia [24 (19%),
4.6], and pyrexia [20 (16%), 3.8]. Number and frequency of TEAEs, excluding infections and injection site reactions,
decreased over the 6-year period from 193 and 173.8, respectively, during year 1 to 37 and 61.3 during year 6. A single
case of malignancy (Hodgkin’s lymphoma) and no cases of active tuberculosis, demyelinating disorders, or deaths were
reported.
Conclusions: Open-label etanercept treatment for up to 6 years was safe, well tolerated, and effective in patients with
eoJIA, ERA, and PsA.
Trial registration: ClinicalTrials.gov: CLIPPER, NCT00962741, registered 20 August, 2009, CLIPPER2, NCT01421069,
registered 22 August, 2011.
Keywords: Etanercept, Juvenile idiopathic arthritis, Enthesitis-related arthritis, Extended oligoarticular juvenile idiopathic
arthritis (eoJIA), Enthesitis-related arthritis (ERA), Psoriatic arthritis (PsA), Efficacy, Safety, Clinical trial
Background
Juvenile idiopathic arthritis (JIA) is a heterogeneous
chronic disease estimated to affect approximately 1 in
1000 children [1–3]. It encompasses seven clinical
categories: systemic arthritis, oligoarticular juvenile
idiopathic arthritis (extended and persistent: eoJIA
and poJIA), rheumatoid factor-positive polyarthritis,
rheumatoid factor-negative polyarthritis, psoriatic
arthritis (PsA), enthesitis-related arthritis (ERA), and
undifferentiated arthritis [4]. Available treatments
have greatly improved clinical outcomes [5–11], but
few have been studied in all JIA categories [5, 12,
13], with long-term data being relatively scarce [14].
Etanercept (ETN), an inhibitor of tumor necrosis
factor alpha (TNFα), was shown to be safe and effi-
cacious in children with polyarticular JIA who re-
ceived up to 8 years of continuous treatment [15,
16], but evidence of long-term benefits in the JIA
categories of eoJIA, ERA, and psoriatic arthritis has
been limited [17, 18].
CLinical Study In Pediatric Patients of Etanercept for
Treatment of ERA, PsA, and Extended Oligoarthritis
(CLIPPER, NCT00962741) was a 2-year open-label
study, designed to assess efficacy and safety of ETN
in pediatric patients with eoJIA, ERA, and PsA [19].
CLIPPER and CLIPPER2 (NCT01421069), its 8-year
long-term extension, will provide efficacy and safety
data for up to 10 years of treatment in this patient
population. Here we present 6-year interim findings,
from 2 years of CLIPPER and 4 years of CLIPPER2,
on safety and efficacy in patients with eoJIA, ERA,
or PsA.
Methods
Patients and study design
Full methodology of the CLIPPER trial was described pre-
viously [8, 19]. Briefly, CLIPPER was a 24-month, Phase
IIIb, open-label multicenter study performed at 38 centers
in 19 member countries of the Paediatric Rheumatology
International Trials Organisation (PRINTO) [20]. Patients
classified as eoJIA (2–17 years of age), ERA (12–17 years),
or PsA (12–17 years) received ETN 0.8 mg/kg (maximum
dose, 50mg) once weekly (QW) for up to 96 weeks. All
participants were required to have ≥ 2 active joints (e.g.,
joints with swelling or with limitation of motion [LOM]
accompanied by either pain or tenderness). Those with
eoJIA or PsA were required to have had an unsatisfac-
tory response or intolerance to a non-biologic disease-
modifying anti-rheumatic drug (DMARD) (e.g., metho-
trexate). Patients with ERA were required to have had
an unsatisfactory response or intolerance to either a
non-biologic DMARD or a non-steroidal anti-inflammatory
drug (NSAID). Individuals previously treated with biologics
were excluded. CLIPPER2 is an on-going, 8-year, open-label
extension study of CLIPPER. Patients who received at least
one dose of ETN and who completed approximately 2 years
of CLIPPER were eligible to enter the active treatment
period of CLIPPER2.
A combined flow chart of CLIPPER and CLIPPER2 is
presented in Fig. 1. All CLIPPER participants who com-
pleted 24months of treatment with ETN were eligible to
enroll in CLIPPER2. Patients who had either met the
American College of Rheumatology (ACR) definition for
JIA clinically inactive disease [21] (CIDACR) for at least 6
months of continuous treatment (clinical remission,
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CRACR) or, in investigator’s judgment, had a good clinical
response and would benefit from etanercept withdrawal,
were eligible to enter the withdrawal period. Those in the
withdrawal period who flared and were in need of ETN
retreatment per the investigator’s clinical judgment could
enter the retreatment period. (flare was defined as ≥ 30%
worsening in at least three of the six ACR Pediatric com-
ponents, with ≥ 30% improvement in not more than one
of the remaining components and a minimum of two ac-
tive joints.) Patients who did not complete 24months of
active treatment in CLIPPER or discontinued ETN for any
reason before the end of CLIPPER2, as well as those in
the withdrawal period who were ineligible for retreatment
with ETN or who discontinued during the retreatment
period, were eligible to enroll into the observational
period of CLIPPER2 and were assessed for safety only,
every 6months until the end of the trial.
Efficacy and safety outcomes
The efficacy endpoints were assessed for up to 72
months of trial participation (24 months of CLIPPER
and 48 months of CLIPPER2) and included the JIA core
set of measures [22]: Physician Global Assessment
(PGA) [23], Patient/Parent Global Assessment (PtGA)
[23], number of active joints and joints with LOM, levels
of C-reactive protein (CRP), and the cross-culturally
adapted and validated version of Childhood Health As-
sessment Questionnaire (CHAQ) [24]. In addition, we
reported the overall back pain and nocturnal back pain
on a 100-mm visual analog scale (VAS) for patients with
ERA; body surface area (BSA; %) affected and PGA of
psoriasis for patients with PsA; proportions of patients
achieving JIA American College of Rheumatology’s
(ACR) 30, 50, 70, 90, and 100 criteria [21], and the
Juvenile Arthritis Disease Activity Score (JADAS) [25]
Fig. 1 Study flow. (a) Patients actively receiving treatment with ETN. (b) Patients who either achieved CRACR or who, in the investigator’s clinical
judgment, had a good clinical response and would benefit from treatment withdrawal. (c) Patients in the withdrawal period who required re-
treatment per the investigator’s clinical judgment and re-started ETN. (d) Patients who stopped treatment but were still followed in CLIPPER2. (e)
Patients who were no longer being followed as part of CLIPPER or CLIPPER2. *Includes two patients who entered the observational period
directly from CLIPPER, plus three patients who entered the observational period from another treatment phase. †Nine out of 22 patients entered
the withdrawal period because of a treatment-emergent adverse event. Abbreviations: CRACR, clinical remission, based on the American College
of Rheumatology criteria [21]
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73-joint inactive disease, JADAS clinically inactive dis-
ease (CIDJADAS) [26] at each visit; and proportions of
patients achieving sustained JIA ACR clinical remission
(CRACR) defined as no joints with active arthritis; no fever,
rash, serositis, splenomegaly, or generalized lymphadenop-
athy attributable to JIA; CRP level within normal limits;
PGA of disease activity score of best possible on the scale
used; duration of morning stiffness of ≤ 15min; and no
active uveitis [21]. CR on medication was defined as per-
sistence of clinically inactive disease (CRACR or CRJADAS
criteria) for ≥ 6 continuous months. Disease activity was
assessed based on the following cut-off values of the
JADAS score: ≤ 1, CID; 1–3.8, low disease activity (LDA);
3.9–10.5, moderate disease activity (MDA); > 10.5, high
disease activity (HDA) [25–27]. Time to disease flare was
assessed for patients who entered the withdrawal period.
Safety outcomes included reports of infections, malig-
nancy, and other treatment-emergent adverse events
(TEAEs) classified as per the latest release of MedDRA.
Statistical analysis
All efficacy and safety analyses were based on the modi-
fied intention-to-treat (mITT) population, defined as all
patients who received at least one dose of ETN.
For the responder analyses, missing values were im-
puted using a hybrid method, based on patients’ enrol-
ment status, trial period at cut-off date, and reasons for
permanent discontinuation (Additional file 1: Table S1).
Specifically, for patients who did not complete CLIPPER,
missing data were considered non-response (non-re-
sponder imputation, NRI). For those who did complete
CLIPPER but did not enroll in CLIPPER2, imputation
was performed using the last observation carried for-
ward (LOCF) approach. For patients enrolled in CLIP-
PER2 and who were in active treatment period at the
cut-off date, observed cases (OC) were used (i.e., there
was no imputation). For those enrolled in CLIPPER2,
patients who were in the withdrawal or retreatment
period at the cut-off date, or who permanently discon-
tinued the trial for pregnancy-related reasons, the LOCF
approach was used, using the last available data from the
active treatment period. For patients enrolled in CLIP-
PER who were in the observational period at the cut-off
date, or who permanently discontinued treatment for
reasons not related to pregnancy, the NRI approach was
used. Finally, for those who enrolled in CLIPPER2 and had
missing values before the protocol amendment that added
efficacy assessments, those who entered the observational
period directly, entered the withdrawal period or dropped
out for reasons related to pregnancy, or had not entered
the withdrawal period and had no efficacy data at the time
of cut-off, the LOCF approach was used. Supporting re-
sponder analyses were conducted using OC and the more
conservative NRI approaches (Additional file 1: Figure S1).
Data are presented as means or proportions (%), with 95%
confidence intervals.
All other efficacy analyses were conducted using the
OC approach. Median time to flare for patients in the
withdrawal period was determined using Kaplan-Maier
analysis.
TEAEs were summarized as numbers of events (n)
and events per 100 patient-years (EP100PY). For patients
in the observational period of CLIPPER2, safety was
assessed by collecting serious AEs only.
Results
Patient disposition and baseline characteristics
Six years after treatment initiation (i.e., after 2 years of
CLIPPER and 4 years of CLIPPER2), 48 (38%) of patients
enrolled in CLIPPER (N = 127) were still receiving eta-
nercept, either continuously (41 [32%]) or as retreatment
(7 [6%]), whereas 6 (5%) stopped treatment due to low/
inactive disease and 36 (28%) because they entered the
observation period during CLIPPER2 (Fig. 1). A total of
37 (29%) patients permanently discontinued trial par-
ticipation: 18 (14%) during CLIPPER and 19 (15%)
during CLIPPER2 (Fig. 1). Additional 36 (28%) stopped
ETN treatment but remained in the observational
period, for a total of 73 (46%) patients who discontinued
the study drug.
Demographic and clinical characteristics of patients en-
tering CLIPPER2 (Table 1) were similar to the population
enrolled in CLIPPER, which were described previously [8].
The proportions of patients with PsA and ERA who en-
tered CLIPPER2 (79% and 82%, respectively) were lower
than the proportion of patients with eoJIA (92%).
The median age of patients with eoJIA (8.0 years) was
lower than the median age of patients with ERA or PsA
(14.0 years for both), which was the consequence of the
study’s inclusion criteria. Most patients with eoJIA and
PsA were female (69% and 78%, respectively), whereas the
majority of patients with ERA were male (84%). After 24
months of etanercept treatment in CLIPPER, there were
differences between the three JIA categories in the mean
values of JADAS score, CRP, number of active joints, and
joints with LOM. Overall, 89% of patients were receiving
DMARDs at baseline of CLIPPER2, with methotrexate be-
ing the most commonly used (72%) (Table 1).
Efficacy
The mean improvements from baseline in JADAS dis-
ease activity at month 24 of CLIPPER were largely main-
tained at month 48 of CLIPPER2 (Fig. 2). A similar
pattern was observed for other measures of disease
activity, as well as for patient-reported outcomes (Add-
itional file 1: Table S2).
In patients with ERA, improvements in back pain and
nocturnal back pain achieved from baseline to month 24
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in CLIPPER (reductions in mean score from 25.9 to 2.4
and from 16.4 to 2.2, respectively) were largely maintained
during the first 48months of CLIPPER2; a similar pattern
was observed for improvements in BSA and PGA of psor-
iasis in patients with PsA (Additional file 1: Table S3).
There was a similar pattern in response rates
across the three JIA categories obtained using the
hybrid method for data imputation, with the stron-
gest initial response in terms of JADAS inactive dis-
ease observed for patients with eoJIA (Fig. 3), which
was supported by analyses conducted using OC-only
and NRI-only methodologies for missing data imput-
ation (Additional file 1: Figure A1).
CRACR or CRJADAS was achieved by 27% (34/127) and
24% (30/127) of all patients, respectively. After 2 years,
there was an apparent overall decline in the proportions
of ACR30–100 responders in patients with eoJIA and
ERA, but not in those with PsA (Fig. 3).
Twenty-two (17%) patients discontinued ETN treatment
due to low activity or inactive disease and entered the
withdrawal period (Fig. 1); of those, 13 (59%) experienced
disease flares, with a median time to flare of 190 days.
Safety
Over the 6 years of trials’ duration, the total exposure to
ETN amounted to 524.4 patient-years. Exposure and
Table 1 Baseline characteristics at enrollment in the open-label extension phase, after 24 months of treatment with etanercept
(baseline CLIPPER2)
eoJIA
n = 55
ERA
n = 31
PsA
n = 23
Total
n = 109
% of CLIPPER 92% (55/60) 82% (31/38) 79% (23/29) 86% (109/127)
Age, yearsa 10.6 (4.6) 16.2 (1.6) 15.8 (2.4) 13.3 (4.5)
Femalea 38 (69) 5 (16) 18 (78) 61 (56)
JIA core set
Physician Global Assessment of disease activity, 0–100 score 1.0 (1.4)
n = 49
0.7 (0.7)
n = 30
0.8 (1.0)
n = 19
0.8 (1.2)
n = 98
Number of active jointsa 0.6 (1.0)
n = 40
0.7 (1.2)
n = 28
1.3 (4.6)
n = 19
0.8 (2.3)
n = 87
Number of joints with LOMa 0.8 (1.1)
n = 40
1.4 (3.2)
n = 28
1.7 (5.0)
n = 19
1.2 (3.0)
n = 87
C-reactive protein, mg/La
(normal < 5 mg/L)
3.9 (8.5)
n = 47
2.7 (4.1)
n = 27
1.1 (0.2)
n = 18
3.0 (6.5)
n = 92
PtGA scorea 1.4 (2.0) 1.0 (1.3) 1.3 (1.5) 1.3 (1.7)
CHAQ scorea 0.3 (0.6)
n = 47
0.1 (0.2)
n = 20
0.2 (0.3)
n = 13
0.2 (0.5)
n = 80
JADAS 73 scorea 3.5 (4.7)
n = 37
2.3 (2.2)
n = 25
3.3 (5.4)
n = 18
3.1 (4.3)
n = 80
Additional measures
Overall back pain VAS, mma –
n = 0
2.3 (4.8)
n = 26
–
n = 0
2.3 (4.8)
n = 26
Nocturnal back pain VAS, mma –
n = 0
2.1 (3.7)
n = 26
–
n = 0
2.1 (3.7)
n = 26
Psoriasis BSA, percentagea –
n = 0
–
n = 0
1.4 (2.4)
n = 19
1.4 (2.4)
n = 19
PGA of psoriasisa –
n = 0
–
n = 0
0.6 (0.9)
n = 19
0.6 (0.9)
n = 19
Baseline therapiesb
Any DMARD 50 (91) 28 (90) 19 (83) 97 (89)
Methotrexate 45 (82) 17 (55) 16 (70) 78 (72)
Oral corticosteroid 7 (13) 7 (23) 1 (4) 15 (14)
Oral NSAID 26 (47) 19 (61) 9 (39) 54 (50)
aMean (SD)
bNumber (percentage)
Abbreviations: BSA, body surface area; CHAQ, Childhood Health Assessment Questionnaire; DMARD, disease-modifying anti-rheumatic drug; eoJIA, extended
oligoarticular juvenile idiopathic arthritis; ERA, enthesitis-related arthritis; JADAS, Juvenile Arthritis Disease Activity Score; JIA, juvenile idiopathic arthritis; LOM,
limitation of motion; NSAID, non-steroid anti-inflammatory drug; PGA, Physician Global Assessment; PtGA, Patient/Parent Global Assessment; PsA, psoriatic
arthritis; SD, standard deviation; VAS, visual assessment scale
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Fig. 2 JADAS 73 Score by visit (observed cases). CI, confidence interval; CID, clinically inactive disease; eoJIA, extended oligoarticular juvenile
idiopathic arthritis; ERA, enthesitis-related arthritis; HDA, high disease activity; JADAS, Juvenile Arthritis Disease Activity Score; LDA, low disease
activity; MDA, moderate disease activity; PsA, psoriatic arthritis
Fig. 3 ACR30–100 and JIA inactive disease response rates by visit (hybrid imputation method). Note: For patients with PsA, values for ACR30 and
ACR50 overlap completely for all visits after week 24. Abbreviations: eoJIA, extended oligoarticular juvenile idiopathic arthritis; ERA, enthesitis-
related arthritis; PsA, psoriatic arthritis
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TEAE occurrence data by JIA category are summarized
in Table 2.
The most frequently reported TEAEs after 6 years of
etanercept treatment, not including infections and injec-
tion site reactions, were headache (n = 28; 5.3 EP100PY),
arthralgia (n = 24; 4.6 EP100PY), pyrexia (n = 20; 3.8
EP100PY), diarrhea (n = 12; 2.3 EP100PY), and leukopenia
(n = 12; 2.3 EP100PY). Of those, more than twofold differ-
ences in EP100PY by JIA category were observed for head-
ache (eoJIA, 4.9; ERA, 3.2; PsA, 9.2), pyrexia (eoJIA, 4.5;
ERA, 1.9; PsA, 3.8), diarrhea (eoJIA, 2.0; ERA, 3.8; PsA,
0.8), and leukopenia (eoJIA, 3.7; ERA, 1.3; PsA, 0.8). Over-
all, the infections were more common in patients with
eoJIA than those with ERA or PsA, with EP1000PY values
of 143, 58, and 98, respectively (Table 2).
In the combined 6 years of treatment, there were a
total of 561 (107.0 EP100PY) treatment-emergent infec-
tions, with the most common being those of the upper
respiratory tract (eoJIA n = 86, 35.0 EP100PY; ERA 20,
12.6; PsA 34, 28.4), pharyngitis (eoJIA 45, 18.3; ERA 21,
13.2; PsA 20, 16.7), gastroenteritis (eoJIA 18, 7.3; ERA 5,
3.2; PsA 8, 6.7), and bronchitis (eoJIA 16, 6.5; ERA 7,
4.4; PsA 3, 2.5). No individual TEAE occurred more than
three times in the same patient. The most frequent TEAEs
(> 5% in any JIA subtype) calculated by the number of pa-
tients reporting (instead of the number of events and
EP100PY) are summarized in Additional file 1: Table S4.
Seven cases of uveitis were reported: three in patients
with eoJIA (mild in severity, and judged by the investiga-
tor not to be related to treatment), two in patients with
ERA (one mild and one moderate in severity, both
judged not related to treatment), and two in the PsA
subgroup (one mild and one moderate in severity,
deemed not related and related to treatment, respect-
ively). There were also four cases of Crohn’s disease: one
in a patient with eoJIA (severe, deemed related to treat-
ment) and three in patients with ERA (two moderate
and one severe, all deemed not related to treatment).
One patient with Crohn’s disease was HLA B27-positive.
A total of 15 patients experienced 19 instances of anemia,
leukopenia, or neutropenia (Additional file 1: Table S4). Of
those, 12 (80%) were taking methotrexate at baseline, which
is comparable with the methotrexate use in the overall trial
population (72%; Table 1). One patient (with eoJIA) who
was receiving methotrexate entered the withdrawal period
because of treatment-emergent leukopenia, but subse-
quently entered the retreatment period.
A single case of malignancy was reported (Hodgkin
lymphoma; Table 2 and Additional file 1: Table S4), in a
patient with eoJIA who was treated with ETN for 27
months and had been receiving methotrexate for ap-
proximately 8 years. There were no deaths or cases of
active tuberculosis or demyelinating disorders.
Discussion
This is the first report on the safety and efficacy of ETN
in patients with eoJIA, ERA, or PsA that spans over 6
years of continuous treatment. The study shows that
treatment with ETN is effective, with acceptable safety
and tolerability. Disease activity measures and PROs were
relatively stable from the previously reported results after
2 years of treatment [19] to the end of year 6 in the
current report, suggesting a long-term maintenance of
clinical benefits. The maintenance of benefits is particu-
larly evident in the OC analysis (Additional file 1: Figure
S1), which, however, included only patients who remained
in the study and is therefore biased toward those with a
satisfactory response to treatment. An opposite bias is
manifest in the NRI analysis, which counts all missing
values as non-responders (Additional file 1: Figure S1) and
Table 2 Etanercept exposure and TEAEs by JIA category
eoJIA
n = 60
ERA
n = 38
PsA
n = 29
Total
N = 127
Exposure, patient-years 245.6 158.9 119.9 524.4
TEAEs (excluding infections and injection site reactions), n (n/100PY) 244 (99.4) 151 (95.0) 90 (75.0) 485 (92.5)
Infections, n (n/100PY) 351 (142.9) 93 (58.5) 117 (97.5) 561 (107.0)
TEAEs causing withdrawal (excluding infections and injection site reactions), n (n/100PY) 5 (2.0) 8 (5.0) 0 13 (2.5)
Infections causing withdrawal, n (n/100PY) 2 (0.8) 0 1 (0.8) 3 (0.6)
Serious TEAEs, n (n/100PY) 11 (4.5) 17 (10.7) 4 (3.3) 32 (6.1)
Serious infections, n (n/100PY) 5 (2.0) 4 (2.5) 4 (3.3) 13 (2.5)
Opportunistic infectionsa, n (n/100PY) 0 1 (0.6) 1 (0.8) 2 (0.4)
Autoimmune disordersb, n (n/100PY) 4 (1.6) 4 (2.5) 2 (1.7) 10 (1.9)
Malignancies, n (n/100PY) 1 (0.4) 0 0 1 (0.2)
aAll opportunistic infections were herpes zoster (recurrent or > 1 dermatome affected)
bUveitis, n = 7; Crohn’s disease, n = 3
cHodgkin lymphoma
Abbreviations: 100PY, 100 patient-years; eoJIA, extended oligoarticular juvenile idiopathic arthritis; ERA, enthesitis-related arthritis; PsA, psoriatic arthritis; TEAE,
treatment-emergent adverse event
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disregards the possibility that patients who discontinued
the trial may indeed have had a clinical response. In order
to reconcile many possible scenarios for non-response
and also account for the fact that 46% of patients discon-
tinued ETN treatment after 6 years, we employed a hybrid
method for missing data imputation, which suggests a
decline in the response of about 15–20 percentage points
between the years 2 and 6, particularly for the more strin-
gent response criteria (ACR50 and above) (Fig. 3). How-
ever, about half of this decline was realized during the first
6 months of CLIPPER2, which raises the possibility that it
could be attributed, at least partially, to treatment dis-
continuation, or other administrative differences be-
tween two separate clinical trials. Despite this decline,
the data demonstrate a substantial long-term effect
over a 6-year period.
Direct comparison of our findings with those from pre-
vious ETN studies in JIA is difficult, due to differences in
time points, response measures, sample size, or JIA dis-
ease categories of the patients enrolled [16–18, 28–33].
With these differences in mind, we point out that 61% of
patients in our study achieved ACR70 response at 48
months, compared to approximately 75% of patients at 4
years in an open-label extension study of ETN in
polyarticular-course JIA [16], and 75% of patients from
the Dutch Arthritis and Biologicals in Children Register at
51months [17]. Similarly, 27% and 24% of patients in our
study achieved sustained clinical remission by ACR or
JADAS criteria, respectively, compared with 24% (10/42)
of patients who had achieved sustained CRACR (ac-
cording to the same definition we used in our trial
[21]) in a small, 4-year study of children with JIA
(predominantly polyarthritis 78%) [34].
Overall, similar rates of TEAEs were observed across
all JIA categories and no new major safety signals were
observed. However, infections were more common in
patients with eoJIA than those with ERA or PsA. Com-
pared with patients with ERA or PsA, the eoJIA subgroup
was younger, had a longer disease duration, had higher
rates of MTX and CS use, and had a higher disease activ-
ity (Table 1) [8], so one or more of these factors may have
accounted for the higher infection rate. TEAEs were less
frequent after the initial 2 years of treatment. Overall, the
TEAE rates were similar to those observed in other
long-term studies of ETN in JIA [16, 18, 19, 31].
One patient with eoJIA developed Hodgkin lymphoma
after 27months of treatment with ETN and methotrexate.
The incidence of Hodgkin lymphoma in post-marketing
ETN data for patients aged 0–17 years was 9.5 per
100,000 patient-years, which is higher than the value for
patients in the same age range for the general US popula-
tion recorded in the Surveillance Epidemiology and End
Results database (0.9 per 100,000 patient-years) [35].
However, patients with JIA cannot be easily compared
with the general population, since both JIA and the exten-
sive pre-treatment with immuno-suppressants, including
methotrexate, have been suggested as additional risk
factors for lymphoma [36, 37], and a retrospective study
of 2000–2014 US claims data did not find an increased
risk of malignancies in TNF-treated children with JIA,
pediatric inflammatory bowel disease, or pediatric plaque
psoriasis [38]. Nevertheless, a possibility must be allowed
that the case of Hodgkin lymphoma observed in our study
could have been related to the patient’s treatment (metho-
trexate, ETN, or both).
The limitations of this study include the non-ran-
domized, open-label design and the relatively low re-
tention of treatment, with many patients with missing
data or lost to follow-up. In addition, because of a late
protocol amendment, efficacy data are not available for all
patients from the beginning of the extension study.
Conclusions
In conclusion, open-label treatment with ETN up to 6
years was safe, well tolerated, and effective in patients
with eoJIA, ERA, and PsA. No new safety signals were
detected.
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